InflaRx N.V (IF0) - Total Liabilities
Based on the latest financial reports, InflaRx N.V (IF0) has total liabilities worth €13.66 Million EUR (≈ $15.97 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
InflaRx N.V - Total Liabilities Trend (2016–2025)
This chart illustrates how InflaRx N.V's total liabilities have evolved over time, based on quarterly financial data. See InflaRx N.V current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
InflaRx N.V Competitors by Total Liabilities
The table below lists competitors of InflaRx N.V ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rentokil Initial PLC
LSE:RTO
|
UK | GBX8.97 Billion |
|
Veritone Inc
NASDAQ:VERI
|
USA | $184.20 Million |
|
Alam Sutera Realty Tbk
JK:ASRI
|
Indonesia | Rp11.48 Trillion |
|
Interactive Digital Technologies
TWO:6486
|
Taiwan | NT$1.53 Billion |
|
Tharimmune Inc.
NASDAQ:THAR
|
USA | $121.22 Million |
|
Chime Ball Technology Co Ltd
TWO:1595
|
Taiwan | NT$1.31 Billion |
|
Betmakers Technology Group Ltd
AU:BET
|
Australia | AU$39.22 Million |
|
Bastogi S.p.A
F:BAOA
|
Germany | €190.94 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down InflaRx N.V's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see InflaRx N.V (IF0) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how InflaRx N.V's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for InflaRx N.V (2016–2025)
The table below shows the annual total liabilities of InflaRx N.V from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €13.66 Million ≈ $15.97 Million |
-6.46% |
| 2024-12-31 | €14.60 Million ≈ $17.07 Million |
-17.16% |
| 2023-12-31 | €17.63 Million ≈ $20.61 Million |
+25.46% |
| 2022-12-31 | €14.05 Million ≈ $16.43 Million |
-29.25% |
| 2021-12-31 | €19.86 Million ≈ $23.22 Million |
+91.83% |
| 2020-12-31 | €10.35 Million ≈ $12.10 Million |
-28.26% |
| 2019-12-31 | €14.43 Million ≈ $16.87 Million |
+84.45% |
| 2018-12-31 | €7.82 Million ≈ $9.15 Million |
+63.52% |
| 2017-12-31 | €4.78 Million ≈ $5.59 Million |
-91.33% |
| 2016-12-31 | €55.21 Million ≈ $64.54 Million |
-- |
About InflaRx N.V
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinic… Read more